Skip to main content
. 2021 Mar 1;4:269. doi: 10.1038/s42003-021-01801-2

Fig. 7. IP2 treatment and a therapeutic cancer vaccine targeting the nischarin-derived epitope synergize to inhibit tumor growth.

Fig. 7

a Experimental setting for the evaluation of the antitumor activity of IP2 in combination with the therapeutic TL9 SLP vaccine. b Individual tumor growth kinetics and (c) tumor size at killing of MCA205 fibrosarcoma subcutaneously inoculated into the right flank of immunocompetent C57BL/6 mice and thereafter injected once a week with the TL9 SLP and twice a week with 24 mg/kg of IP2. d Kaplan–Meier survival curves of MCA205 fibrosarcoma-bearing immunocompetent C57BL/6 treated concomitantly with the TL9 SLP and 24 mg/kg of IP2 for 2 weeks. Log-rank (Mantel–Cox) test were performed for survival analysis. *P < 0.05, ***P < 0.001 (One-way ANOVA).